Malaria Vaccine Development Branch (MVDB)

Saul, Allan

Abstract

Malaria Vaccine Development Branch (MVDB) General Description: The Malaria Vaccine Development Unit (MVDU) is an NIAID initiative working in close collaboration with DMID to respond to the global need for vaccines against malaria. We now have produced eight cGMP recombinant protein products: AMA1-FVO, AMA1-3D7, AMA1-L32, MSP1(42)-FVO, MSP1(42)-3D7, MSP1(42)-FUP, Pfs25, Pvs25. Six of these antigens (Pvs25H, Pfs25, AMA1-FVO, AMA1-3D7, MSP1(42)-FVO and MSP1(42)-3D7) are in a series of human Phase 1 vaccine trials, either alone or in combinations using three anjuvants (Aluminum hydroxide, Montanide ISA51 and Aluminum hydroxide with CPG7909). These Phase 1 trials are underway in the USA and in an endemic population in Mali in collaboration with the University of Bamako, Mali. These vaccine trials form part of a clinical development plan working towards Phase 2 trials in an endemic area that will determine if these vaccines are able to make a substantial impact on parasite growth or transmission.

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: National Institute of Allergy and Infectious Diseases (NIAID)
• Type: Intramural Research (Z01)
• Project #: 1Z01AI000727-11
• Application #: 7194119
• Study Section: (LPD)
• Support Year: 11
• Fiscal Year: 2005

Institution

• Name: Niaid Extramural Activities
• Country: United States

Publications

Shimp Jr, Richard L; Martin, Laura B; Zhang, Yanling et al. (2006) Production and characterization of clinical grade Escherichia coli derived Plasmodium falciparum 42 kDa merozoite surface protein 1 (MSP1(42)) in the absence of an affinity tag. Protein Expr Purif 50:58-67

Singh, Sanjay; Miura, Kazutoyo; Zhou, Hong et al. (2006) Immunity to recombinant plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74:4573-80

Collins, William E; Barnwell, John W; Sullivan, Joann S et al. (2006) Assessment of transmission-blocking activity of candidate Pvs25 vaccine using gametocytes from chimpanzees. Am J Trop Med Hyg 74:215-21

Tsai, Chiawei W; Duggan, Peter F; Shimp Jr, Richard L et al. (2006) Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris. J Biotechnol 121:458-70

Makobongo, Morris O; Keegan, Brian; Long, Carole A et al. (2006) Immunization of Aotus monkeys with recombinant cysteine-rich interdomain region 1 alpha protects against severe disease during Plasmodium falciparum reinfection. J Infect Dis 193:731-40

Wille-Reece, Ulrike; Flynn, Barbara J; Lore, Karin et al. (2006) Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates. J Exp Med 203:1249-58

Giersing, Birgitte K; Dubovsky, Filip; Saul, Allan et al. (2006) Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 24:4264-70

Trinh, Loc; Phue, Je-Nie; Jaluria, Pratik et al. (2006) Screen-less expanded bed column: new approach for the recovery and purification of a malaria transmission blocking vaccine candidate from Pichia pastoris. Biotechnol Lett 28:951-8

Saxena, Ajay K; Singh, Kavita; Su, Hua-Poo et al. (2006) The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms. Nat Struct Mol Biol 13:90-1

Mullen, Gregory E D; Giersing, Birgitte K; Ajose-Popoola, Olubunmi et al. (2006) Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine 24:2497-505